Gavin Ha
gha@fredhutch.orgFred Hutch,
Cancer Biology
Computational Biology
Genetics, Genomics & Evolution
1100 Fairview Ave N
Faculty Contact Information
Lab Information
Accepting Students For:
Publications
Shulman DS, Klega K, Imamovic-Tuco A, Clapp A, Nag A, Thorner AR, Van Allen E, Ha G, Lessnick SL, Gorlick R, Janeway KA, Leavey PJ, Mascarenhas L, London WB, Vo KT, Stegmaier K, Hall D, Krailo MD, Barkauskas DA, DuBois SG, Crompton BD.
British journal of cancer. 2019; 120(8):869.
- PMID:
- 30880335
- PMCID:
- PMC6474275
Detection of Circulating Tumor DNA in Patients With Leiomyosarcoma With Progressive Disease.
Hemming ML, Klega KS, Rhoades J, Ha G, Acker KE, Andersen JL, Thai E, Nag A, Thorner AR, Raut CP, George S, Crompton BD.
JCO precision oncology. 2019; 2019. NIHMSID: NIHMS1008513
- PMID:
- 30793095
- PMCID:
- PMC6380497
Tumor fraction in cell-free DNA as a biomarker in prostate cancer.
Choudhury AD, Werner L, Francini E, Wei XX, Ha G, Freeman SS, Rhoades J, Reed SC, Gydush G, Rotem D, Lo C, Taplin ME, Harshman LC, Zhang Z, O'Connor EP, Stover DG, Parsons HA, Getz G, Meyerson M, Love JC, Hahn WC, Adalsteinsson VA.
JCI insight. 2018; 3(21).
- PMID:
- 30385733
- PMCID:
- PMC6238737
Shulman DS, Klega K, Imamovic-Tuco A, Clapp A, Nag A, Thorner AR, Van Allen E, Ha G, Lessnick SL, Gorlick R, Janeway KA, Leavey PJ, Mascarenhas L, London WB, Vo KT, Stegmaier K, Hall D, Krailo MD, Barkauskas DA, DuBois SG, Crompton BD.
British journal of cancer. 2018; 119(5):615-621.
- PMID:
- 30131550
Genetic and transcriptional evolution alters cancer cell line drug response.
Ben-David U, Siranosian B, Ha G, Tang H, Oren Y, Hinohara K, Strathdee CA, Dempster J, Lyons NJ, Burns R, Nag A, Kugener G, Cimini B, Tsvetkov P, Maruvka YE, O'Rourke R, Garrity A, Tubelli AA, Bandopadhayay P, Tsherniak A, Vazquez F, Wong B, Birger C, Ghandi M, Thorner AR, Bittker JA, Meyerson M, Getz G, Beroukhim R, Golub TR.
Nature. 2018; 560(7718):325-330. NIHMSID: NIHMS977514
- PMID:
- 30089904
- PMCID:
- PMC6522222
Genomic discovery and clonal tracking in multiple myeloma by cell-free DNA sequencing.
Guo G, Raje NS, Seifer C, Kloeber J, Isenhart R, Ha G, Yee AJ, O'Donnell EK, Tai YT, Richardson PG, Bianchi G, Laubach JP, Warren D, Gemme E, Voisine J, Frede J, Kokkalis A, Yun H, Dimitrova V, Vijaykumar T, Meyerson M, Munshi NC, Anderson KC, Knoechel B, Lohr JG.
Leukemia. 2018; 32(8):1838-1841. NIHMSID: NIHMS977775
- PMID:
- 29749395
- PMCID:
- PMC6160352
Viswanathan SR, Ha G, Hoff AM, Wala JA, Carrot-Zhang J, Whelan CW, Haradhvala NJ, Freeman SS, Reed SC, Rhoades J, Polak P, Cipicchio M, Wankowicz SA, Wong A, Kamath T, Zhang Z, Gydush GJ, Rotem D, Love JC, Getz G, Gabriel S, Zhang CZ, Dehm SM, Nelson PS, Van Allen EM, Choudhury AD, Adalsteinsson VA, Beroukhim R, Taplin ME, Meyerson M.
Cell. 2018; 174(2):433-447.e19. NIHMSID: NIHMS974515
- PMID:
- 29909985
- PMCID:
- PMC6046279
Klega K, Imamovic-Tuco A, Ha G, Clapp AN, Meyer S, Ward A, Clinton C, Nag A, Van Allen E, Mullen E, DuBois SG, Janeway K, Meyerson M, Thorner AR, Crompton BD.
JCO precision oncology. 2018; 2018. NIHMSID: NIHMS980370
- PMID:
- 30027144
- PMCID:
- PMC6049092
Whole-exome sequencing of cell-free DNA and circulating tumor cells in multiple myeloma.
Manier S, Park J, Capelletti M, Bustoros M, Freeman SS, Ha G, Rhoades J, Liu CJ, Huynh D, Reed SC, Gydush G, Salem KZ, Rotem D, Freymond C, Yosef A, Perilla-Glen A, Garderet L, Van Allen EM, Kumar S, Love JC, Getz G, Adalsteinsson VA, Ghobrial IM.
Nature communications. 2018; 9(1):1691.
- PMID:
- 29703982
- PMCID:
- PMC5923255
Genomic and Functional Approaches to Understanding Cancer Aneuploidy.
Taylor AM, Shih J, Ha G, Gao GF, Zhang X, Berger AC, Schumacher SE, Wang C, Hu H, Liu J, Lazar AJ, Cherniack AD, Beroukhim R, Meyerson M.
Cancer cell. 2018; 33(4):676-689.e3. NIHMSID: NIHMS958047
- PMID:
- 29622463
- PMCID:
- PMC6028190
Research Summary
My laboratory is interested in studying the role of genomic alterations in cancer and expanding applications for precision medicine. We develop novel algorithms to identify genomic structural alterations in tumor and circulating cell-free DNA from patients with cancer. Our goals are to uncover the genetic and epigenetic mechanisms of treatment resistance, to identify blood-based genomic biomarkers, and to translate these findings and innovations to advance clinical research and precision medicine.